|
|
|
 |
|
 |
 |
|||
Company News
|
ABLYNX RAISES €75 MILLION IN SUCCESSFUL IPO - Largest ever biotech IPO on Euronext Brussels
Ghent, Belgium, 06 November 2007
top
Syntaxin raises £16M to advance development of novel drug pipeline
Oxford, UK, 31 October 2007
top
Entelos Raises $2m via Abingworth Share Purchase
Foster City, CA, 19 September 2007
top
ABLYNX AND BOEHRINGER INGELHEIM ANNOUNCE MAJOR GLOBAL STRATEGIC ALLIANCE TO DISCOVER, DEVELOP AND COMMERCIALISE NOVEL NANOBODY®
GHENT, Belgium and INGELHEIM, Germany, 07 September 2007
top
Entelos Acquires Iconix Biosciences, Inc.
Foster City, CA, 30 August 2007
top
Roche and Alnylam Form Major Alliance on RNAi Therapeutics
Nutley, N.J., 09 July 2007
top
Portola Pharmaceuticals, Inc. Announces Completion of $70 Million Series C
Portola to Advance Development of its Two Anti-thrombotic Clinical Candidates
South San Francisco, CA, 07 May 2007
top
Abingworth appoints Vincent Miles as Venture Partner
Waltham, MA, US, and London, UK, 14 March 2007
top
Abingworth wins European Venture Capital Journal Award
VC House of the Year – Life Sciences
London, UK, 06 February 2007
top
Abingworth raises Europe’s largest ever life sciences venture fund
ABV V closes on £300 million
London, UK, 29 January 2007
top
NOVEXEL RAISES €50 MILLION IN A SERIES B ROUND
Largest European private funding in the biotech sector in the last twelve months
Paris, France, 08 January 2007
top
Prosensa raises $18 million Series A financing led by LSP and Abingworth
Leiden, Netherlands, 05 January 2007
top
Roche and Synosis Therapeutics announce partnership to explore potential of five compounds targeting the central nervous system
Basel, Switzerland and South San Francisco, CA, 04 January 2007
top
|
Archive:
|
|||||||||||||||||||||||||||||||||||||||||||||
2013
Andrew Kay, President and CEO of Algeta
Abingworth set a highly professional tone from the beginning. The due diligence was detailed and incisive and this attention to detail continued as Algeta became one of their portfolio companies. It is Abingworth's support capability that really distinguishes them. This includes market analytics, finance, commercial intelligence, and search expertise for executive managers and board members. They have extensive networks with big companies, biotechs and banks that provides invaluable introductions and contacts. What is quite remarkable is that despite being one of many portfolio companies, everyone across the Abingworth organisation seems to know who you are and they are responsive and enthusiastic about thinking of ways to help, identifying opportunities, issues and solutions.